ESTRO 2024 - Abstract Book

S1133

Clinical - Haematology

ESTRO 2024

Keywords: Cutaneous T-cell lymphoma, Mycosis Fungoides

References:

1. Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015 Nov 10;33(32):3766-73.

396

Proffered Paper

The UK experience of Proton Beam Therapy for the treatment of lymphoma in teenagers and young adults

Emma K Austin 1 , Christian Brunet 2 , Yen C Chang 1,3 , Frances Charlwood 4 , Andrew Gosling 2 , Christina Hague 5 , Karim Keshwani 1 , Maria Kilkenny 6 , Pei Lim 1 , Ed Smith 5,7 , Clara Chan 5 , Suganya Sivabalasingham 1 1 University College London Hospitals, Dept of Clinical Oncology, London, United Kingdom. 2 University College London Hospitals, Medical Physics and Engineering, London, United Kingdom. 3 University College London Hospitals, Proton Clinical Outcomes Unit, London, United Kingdom. 4 The Christie NHS Foundation Trust, Medical Physics and Engineering, Manchester, United Kingdom. 5 The Christie NHS Foundation Trust, Dept of Clinical Oncology, Manchester, United Kingdom. 6 University College London Hospitals, Radiotherapy Radiographer, London, United Kingdom. 7 The Christie NHS Foundation Trust, Proton Clinical Outcomes Unit, Manchester, United Kingdom Pencil beam proton therapy (PBT) delivers highly conformal, intensity modulated radiotherapy (RT) whilst enhancing normal tissue sparing. The UK has been treating patients with select commissioned indications at two centres since 2018. Radiotherapy is often a component of curative treatment for lymphoma. These patients are young and typically have excellent clinical outcomes, therefore reduction of late treatment-related morbidity and mortality is essential. PBT has dosimetric advantages over photons, not least with reducing the total irradiated volume and potential late toxicities. Although, there is no high-level evidence demonstrating clinical superiority of PBT to photons for this group currently, the rationale for PBT in teenagers and young adults (TYA) lymphoma patients is compelling. Routine national commissioning for TYA lymphoma patients is due to open in late 2023. We have undertaken a service development program to optimise the pathway and assess feasibility and acute toxicity in this group of patients. Purpose/Objective:

Material/Methods: